파라택시스코리아
288330KOSDAQ54.5 / 100
Reference Date: 2026-09-08
Company InformationBased on 2025 Annual Report
Business Overview
Parataxis Korea operates two main business segments: digital assets and biotechnology. In the digital asset division, the company holds Bitcoin as a strategic financial asset and aims to generate revenue through mining operations. The biotechnology division focuses on developing innovative drugs for unmet medical needs, with key candidates like BBT-207 and BBT-877 currently in clinical trials for lung cancer and idiopathic pulmonary fibrosis, respectively.
Number of Employees
16people
Average Salary
74.5M KRW
Score Calculation Basis
Detailed Financial Score
In line with industry avg
Well below industry avg
Half of industry avg (excellent)
Avg ▲107.7% (2-year basis)
Avg ▲36.6% (2-year basis)
Avg ROE -97.2% (improving, 3yr)
Detailed News Sentiment
- Neutral파라택시스이더리움, 합병 특별위 구성…"주주권익 독립 검토"
합병 특별위원회 구성으로 주주 권익 보호 강화 논의 중이나, 직접적인 주식 가치 영향은 명확하지 않음.
Detailed Momentum
Near 52w low (0%, downtrend)
1m 0% (flat)
Volume surge
Detailed Disclosure
- Neutral주권매매거래정지 (투자자 보호)2026-08-20
- Neutral기타시장안내 (정리매매 보류 관련)2026-08-20
- Neutral기타경영사항(자율공시) (상장폐지 결정 효력정지 가처분신청)2026-08-20
- Neutral기타시장안내 (코스닥시장위원회 개최 결과 및 상장폐지 결정 안내)2026-08-19
- Neutral반기보고서 (2026.06)2026-08-14
